# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $4 to $5.
Company announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a ...
Ocugen shares are trading higher by 7.7% during Monday's session. The company announced U.S. FDA clearance of the IND amend...
The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the oth...